Myelofibrosis laboratory tests: Difference between revisions

Jump to navigation Jump to search
Line 22: Line 22:
*[[megakaryocytes|Dysplastic megakaryocytes]]
*[[megakaryocytes|Dysplastic megakaryocytes]]


===JAK2 Mutation Analysis Testing===
*''[[JAK 2]]'' mutation on Val 617 Phe locus in 50%




* JAK 2 mutation on Val 617 Phe locus in 50%
* Raised levels of [[lactate dehydrogenase]]
* Raised levels of [[lactate dehydrogenase]]
* Raised neutrophil alkaline phosphatase score
* Raised neutrophil alkaline phosphatase score

Revision as of 16:35, 8 March 2016

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis laboratory tests

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis laboratory tests

CDC on Myelofibrosis laboratory tests

Myelofibrosis laboratory tests in the news

Blogs on Myelofibrosis laboratory tests

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

Laboratory Tests

Laboratory findings consistent with the diagnosis of myelofibrosis include:[1]

Complete Blood Count

Peripheral Blood Smear

  • Presence of nucleated red blood cells suggests that immature cells are being released into the bloodstream in response to a very high demand for the bone marrow to produce new red blood cells.

JAK2 Mutation Analysis Testing

  • JAK 2 mutation on Val 617 Phe locus in 50%


TB testing

The patient with the myelofibrosis should be tested for Tuberculosis even if the patient doesn't manifest the symptoms of TB. There is strong evidence of myelofibrois improvement with the antituberculous treatment.

References

  1. Diagnosis of myelofibrosis. Wikipedia 2016. https://en.wikipedia.org/wiki/Myelofibrosis. Accessed on March 8, 2016


Template:WikiDoc Sources